Switch to:

Trevi Therapeutics Cash-to-Debt

: 3.79 (As of Sep. 2020)
View and export this data going back to 2019. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Trevi Therapeutics's cash to debt ratio for the quarter that ended in Sep. 2020 was 3.79.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Trevi Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Sep. 2020.

NAS:TRVI' s Cash-to-Debt Range Over the Past 10 Years
Min: 3.79   Med: 156.57   Max: 178.92
Current: 3.79
3.79
178.92

During the past 3 years, Trevi Therapeutics's highest Cash to Debt Ratio was 178.92. The lowest was 3.79. And the median was 156.57.

NAS:TRVI's Cash-to-Debt is ranked lower than
64% of the 1228 Companies
in the Biotechnology industry.

( Industry Median: 9.83 vs. NAS:TRVI: 3.79 )

Trevi Therapeutics Cash-to-Debt Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

Trevi Therapeutics Annual Data
Dec17 Dec18 Dec19
Cash-to-Debt 4.17 156.57 160.99

Trevi Therapeutics Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
Cash-to-Debt Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 168.03 160.99 158.55 143.44 3.79
Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.

Trevi Therapeutics Cash-to-Debt Distribution

* The bar in red indicates where Trevi Therapeutics's Cash-to-Debt falls into.


Trevi Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Trevi Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2019 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=57.313 / (0.099 + 0.257)
=160.99

Trevi Therapeutics's Cash to Debt Ratio for the quarter that ended in Sep. 2020 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=53.293 / (0.11 + 13.971)
=3.78

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

Trevi Therapeutics  (NAS:TRVI) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Trevi Therapeutics Cash-to-Debt Related Terms

Trevi Therapeutics Cash-to-Debt Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)